Jinan Hongyuan Chemical Co.,Ltd
86-13954187575
On January 5, 2021, AXA announced that the US Food and Drug Administration (FDA) recently granted the company the qualification of the orphan drug apg-2575, an original Bcl-2 inhibitor, for the
In July this year, the State Food and Drug Administration issued a notice on the implementation of the Pharmacopoeia of the people's Republic of China 2020, which is now December 31, 2020, which means
Since 2018, China's a new force suddenly rises. With the support of national policies, the domestic innovative drugs have been effective in the following aspects: efficacy, safety, reliability, and pr
1. Change of ownership On December 20, according to Xinhua news, Tianjin Jinlian Investment Holding Co., Ltd. (hereinafter referred to as "Jinlian holding") and Shanghai
National Medical Insurance Bureau issued the "operation standard of medical price and bidding and purchasing credit evaluation (2020 Edition)" Recently, the State Medical Insurance Bure
Recently, the drug administration of Shanxi Province issued the work plan for the construction of drug information traceability system. By the end of 2020, the basic development of drug traceability a
China is one of the largest API producers in the world. After decades of development, China has formed a relatively complete industrial system. In recent years, after adjustment and upgrading, the API
Investment strategy of API in November: stricter environmental protection policy, overall good, focus on vitamins and antibiotic intermediates Core ideas Vitamin industry
Privacy statement: Your privacy is very important to Us. Our company promises not to disclose your personal information to any external company with out your explicit permission.
Fill in more information so that we can get in touch with you faster
Privacy statement: Your privacy is very important to Us. Our company promises not to disclose your personal information to any external company with out your explicit permission.
